$RPRX: Reported "Positive" clinical data couple of days ago that oral administration of Proellex at doses of both 6 and 12 mg achieved significant reduction in excessive menstrual bleeding, the key symptom of uterine fibroids. Highlights:

Primary endpoint of induction of amenorrhea met for the pooled oral doses compared to placebo, p=0.0004Proellex-treated subjects reported a median 100% (mean 95%) reduction in diary reports of menstrual bleeding product usage (PBAC)Statistically significant reduction in fibroid size from baseline achieved for the combined active arms compared to increase in fibroid volume in placebo arm, p=0.0007